If the cells are truly a commodity, the only thing in-sourcing gets you in terms of profit is the opportunity to beat the market on demand prediction (that is, you may over-spend on production and not actually benefit from your capacity predictions).

There's a similar effect with the component properties. Really, you are looking at the properties per dollar spent, so if you take a wrong term, in-sourcing costs you relative to the market.